Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,850.00-0.36%ETH$2,261.28+0.13%GOLD$3,968.20+0.71%OIL$95.60-0.51%
Smart Investors Daily
SID Premium
OL

NASDAQ · OLMA

Olema Pharmaceuticals, Inc.

Healthcare · Biotechnology

$7.35

Up+$0.28 (+3.96%)

Updated Nov 4, 2026, 9:12 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.17B
P/E ratio
-18.05
Dividend yield
0.00%
52-week range
$6.24 – $36.26
Volume
1.21M
Avg. volume
3.41M

Price performance · OLMA

OLMA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

OLMA closed at $7.35 after 21 trading sessions, down 7.20% for the selected period.

Last close
$7.35
Period change
-7.20%
Period low
$6.41
Period high
$7.94
Daily close
View OHLC price history
OLMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$7.12$7.41$7.00$7.351.21M
Nov 2, 2026$7.00$7.13$6.7101$7.071.12M
Oct 30, 2026$7.22$7.44$6.92$7.00751.36K
Oct 29, 2026$7.50$7.60$7.14$7.331.15M
Oct 28, 2026$6.93$7.49$6.81$7.491.44M
Oct 27, 2026$6.62$7.13$6.49$7.042.19M
Oct 26, 2026$6.44$6.78$6.34$6.621.99M
Oct 23, 2026$6.93$6.94$6.235$6.411.98M
Oct 22, 2026$6.96$7.10$6.83$7.021.06M
Oct 21, 2026$7.24$7.47$7.03$7.051.24M
Oct 20, 2026$7.12$7.61$7.085$7.251.87M
Oct 19, 2026$6.68$7.255$6.68$7.111.27M
Oct 16, 2026$6.83$6.83$6.48$6.581.08M
Oct 15, 2026$6.84$6.945$6.70$6.871.09M
Oct 14, 2026$6.92$7.15$6.61$6.801.85M
Oct 13, 2026$7.30$7.3627$6.99$7.022.01M
Oct 12, 2026$7.77$7.77$7.33$7.361.02M
Oct 9, 2026$7.77$8.00$7.725$7.82758.25K
Oct 8, 2026$7.87$8.21$7.56$7.821.4M
Oct 7, 2026$7.90$8.23$7.79$7.94819.46K
Oct 6, 2026$8.28$8.29$7.80$7.921.04M

Latest OLMA news

The latest Smart Investors Daily articles mentioning OLMA.

Stock researchCompany · Overview

OLMA research

Overview

Company profile and research snapshot.

Company profile

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.80
Implied upside
—
Analysts
—
OLMA recent ratings
DateFirmRatingTarget
Sep 14, 2026StifelBuy—
Aug 13, 2026JP MorganOverweight—
Aug 11, 2026CitigroupBuy—
Aug 11, 2026HC Wainwright & Co.Buy—
May 13, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 2, 2026

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation ConferenceDate and Time: November 10, 2026 at 10 a.m. ETFormat: Fireside ChatLoc

Yahoo · Oct 5, 2026

SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight

DelveInsight's SERD Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as ER+/HER2- breast cancer, Endometrial cancer, HER2+ breast cancer, Ovarian cancer, ESR1 mutated breast cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emergi

Yahoo · Oct 2, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By